Summary Slide.png (118.93 kB)
Download fileOral Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
figure
posted on 2021-01-18, 11:24 authored by Adis journals on behalf of, Richard E. Pratley, Matthew J. Crowley, Mette Gislum, Christin L. Hertz, Thomas B. Jensen, Kamlesh Khunti, Ofri Mosenzon, John B. BuseArticle full text
The above summary slide and graphical abstract represent the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
